REMUS — Remus Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapHigh Flyer

Annual income statement for Remus Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st
Period Length:	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	ARS
Standards:	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final
Revenue
Total Revenue	119	184	247	450
Cost of Revenue
Gross Profit	48.8	69.2	124	236
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	116	178	208	350
Operating Profit	2.87	5.87	39.2	101
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	10.9	13.6	45.5	114
Provision for Income Taxes
Net Income After Taxes	8.12	10.3	33.9	85
Net Income Before Extraordinary Items
Net Income	8.12	10.3	33.9	85
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8.12	10.3	33.9	85
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.38	1.74	5.75	20.8
Dividends per Share